CL2018001065A1 - Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents
Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vihInfo
- Publication number
- CL2018001065A1 CL2018001065A1 CL2018001065A CL2018001065A CL2018001065A1 CL 2018001065 A1 CL2018001065 A1 CL 2018001065A1 CL 2018001065 A CL2018001065 A CL 2018001065A CL 2018001065 A CL2018001065 A CL 2018001065A CL 2018001065 A1 CL2018001065 A1 CL 2018001065A1
- Authority
- CL
- Chile
- Prior art keywords
- union
- prevention
- treatment
- triespecific
- binding proteins
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013024 troubleshooting Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
EN LA PRESENTE MEMORIA SE PROPORCIONAN QUE COMPRENDEN PROTEÍNAS DE UNIÓN TRIESPECÍFICAS Y/O TRIVALENTES QUE COMPRENDEN CUATRO CADENAS POLIPEPTIDICAS QUE FORMAN TRES SITIOS DE UNIÓN A ANTÍGENO QUE SE UNEN ESPECÍFICAMENTE A UNA O MÁS PROTEÍNAS DIANA DE¡ VIH O UNO O MÁS RECEPTORES DE CÉLULAS T, EN DONDE UN PRIMER PAR DE POLIPÉPTIDOS QUE FORMAN LA PROTEÍNA DE UNIÓN POSEE DOMINIOS VARIABLES DUALES QUE TIENEN UNA ORIENTACIÓN CRUZADA Y EN DONDE UN SEGUNDO PAR DE POLIPÉPTIDOS QUE FORMAN LA PROTEÍNA DE UNIÓN POSEE UN SOLO DOMINIO VARIABLE. TAMBIÉN SE PROPORCIONAN EN LA PRESENTE MEMORIA MÉTODOS PARA PREPARAR PROTEÍNAS DE UNIÓN TRIESPECÍFICAS Y/O TRIVALENTES Y USOS DE TALES PROTEÍNAS DE UNIÓN PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE VIH/SIDA.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246113P | 2015-10-25 | 2015-10-25 | |
EP16305211 | 2016-02-24 | ||
US201662322029P | 2016-04-13 | 2016-04-13 | |
US201662331169P | 2016-05-03 | 2016-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001065A1 true CL2018001065A1 (es) | 2018-11-23 |
Family
ID=55588187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001065A CL2018001065A1 (es) | 2015-10-25 | 2018-04-23 | Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih |
Country Status (31)
Country | Link |
---|---|
US (3) | US20190054182A1 (es) |
EP (2) | EP3819310A1 (es) |
JP (3) | JP7169190B2 (es) |
KR (1) | KR20180063336A (es) |
CN (4) | CN117069855A (es) |
AR (1) | AR106466A1 (es) |
AU (2) | AU2016347058B2 (es) |
BR (1) | BR112018008011A2 (es) |
CA (1) | CA3002664A1 (es) |
CL (1) | CL2018001065A1 (es) |
CO (1) | CO2018005337A2 (es) |
CR (1) | CR20180288A (es) |
DO (1) | DOP2018000102A (es) |
EA (1) | EA201891028A1 (es) |
ES (1) | ES2894304T3 (es) |
HK (1) | HK1253385A1 (es) |
HR (1) | HRP20211528T1 (es) |
HU (1) | HUE056608T2 (es) |
IL (2) | IL301140A (es) |
MA (1) | MA42641A1 (es) |
MX (2) | MX2018005048A (es) |
MY (1) | MY192278A (es) |
PE (1) | PE20181167A1 (es) |
PH (1) | PH12018500873A1 (es) |
PL (1) | PL3365366T3 (es) |
RS (1) | RS62437B1 (es) |
SG (1) | SG11201803324VA (es) |
SI (1) | SI3365366T1 (es) |
TW (2) | TWI750139B (es) |
UY (1) | UY36965A (es) |
WO (1) | WO2017074878A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
EP3110844B1 (en) * | 2014-02-28 | 2020-02-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
AU2016347058B2 (en) * | 2015-10-25 | 2023-11-09 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection |
CN108884149B (zh) * | 2015-11-03 | 2022-07-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1 gp41中和抗体及其用途 |
DK3443006T5 (da) | 2016-04-13 | 2023-11-06 | Sanofi Sa | Trispecifikke og/eller trivalente bindingsproteiner |
SG11201808911SA (en) * | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
CA3065328C (en) | 2017-06-21 | 2023-08-15 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
CN111788225A (zh) * | 2017-10-10 | 2020-10-16 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
CA3085351A1 (en) * | 2017-12-21 | 2019-07-11 | Aaron Diamond Aids Research Center | Bispecific hiv-1-neutralizing antibodies |
MX2020007444A (es) | 2018-01-12 | 2020-09-14 | Genzyme Corp | Metodos para la cuantificacion de polipeptidos. |
EP3797118A4 (en) | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
SG11202103478RA (en) * | 2018-10-09 | 2021-05-28 | Sanofi Sa | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
US20220025021A1 (en) * | 2018-11-21 | 2022-01-27 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
EP3953388A1 (en) | 2019-04-09 | 2022-02-16 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
CA3155356A1 (en) | 2019-10-25 | 2021-04-29 | Fateme TOUSI | Methods for analyzing chain mispairing in multispecific binding proteins |
WO2021203103A2 (en) * | 2020-04-03 | 2021-10-07 | Somasekar Seshagiri | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
AU2021333577A1 (en) * | 2020-08-25 | 2023-03-30 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
TW202334204A (zh) * | 2021-12-21 | 2023-09-01 | 美商莫德斯醫療公司 | 條件性活化之抗原結合多肽複合物及其使用方法 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
EP1641826A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN103403026B (zh) | 2009-09-25 | 2016-05-11 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1中和抗体及其用途 |
SI2580243T1 (sl) | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
PT2710033T (pt) * | 2011-05-17 | 2021-03-11 | Univ Rockefeller | Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes |
RU2624046C2 (ru) | 2011-11-07 | 2017-06-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Gp41-нейтрализующие антитела и их применение |
CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
WO2013086533A1 (en) | 2011-12-08 | 2013-06-13 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
EP2900696A1 (en) * | 2012-09-25 | 2015-08-05 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
EP2928924A4 (en) | 2012-12-04 | 2016-07-13 | Univ Maryland | HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE |
CA2889723A1 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
CN104936986B (zh) * | 2013-02-26 | 2019-08-09 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
TW201446800A (zh) | 2013-03-15 | 2014-12-16 | Abbvie Inc | 針對TNFα之雙特異性結合蛋白 |
WO2015017755A1 (en) | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
SG10201909806SA (en) | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
ME03666B (me) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
CA2996848C (en) | 2014-09-04 | 2021-01-05 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
MA40801A1 (fr) | 2015-01-23 | 2018-07-31 | Sanofi Sa | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
MX2022001187A (es) | 2015-05-20 | 2023-01-04 | Quantum Si Inc | Método para determinar la secuencia de un ácido nucleico usando luminiscencia resuelta por tiempo. |
US10654943B2 (en) | 2015-06-02 | 2020-05-19 | The Rockefeller University | Tri-specific antibodies for HIV therapy |
EA201890782A1 (ru) | 2015-09-22 | 2018-09-28 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способ перенацеливания t-клеток для лечения инфекции hiv |
AU2016347058B2 (en) | 2015-10-25 | 2023-11-09 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection |
CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞 |
EA202091898A1 (ru) | 2015-12-15 | 2021-06-22 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
DK3443006T5 (da) | 2016-04-13 | 2023-11-06 | Sanofi Sa | Trispecifikke og/eller trivalente bindingsproteiner |
SG11201808911SA (en) | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
US20230242876A1 (en) | 2016-12-30 | 2023-08-03 | Shanghai Sinobio Biotech Co., Ltd. | Bifunctional molecule and use thereof |
KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
WO2018183294A1 (en) | 2017-03-27 | 2018-10-04 | David Weiner | Dna antibody constructs for use against hiv |
CN111788225A (zh) | 2017-10-10 | 2020-10-16 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
SG11202103478RA (en) | 2018-10-09 | 2021-05-28 | Sanofi Sa | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en active Application Filing
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 BR BR112018008011A patent/BR112018008011A2/pt active Search and Examination
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 KR KR1020187014534A patent/KR20180063336A/ko active IP Right Grant
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
- 2018-10-04 HK HK18112682.8A patent/HK1253385A1/zh unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP2023085476A/ja active Pending
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001065A1 (es) | Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
CO2018012107A2 (es) | Proteínas de unión triespecíficas y/o trivalentes | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
EA201892386A1 (ru) | Химерные нейротоксины | |
PE20170767A1 (es) | Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
CL2019002626A1 (es) | Anticuerpos anti-par2 y usos de los mismos. | |
MX355107B (es) | Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus. | |
EA201692552A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
BR112017009764A2 (pt) | anticorpos biespecíficos e métodos de uso em oftalmologia | |
EA201691429A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
CR20170020A (es) | Variantes de proteínas de unión al factor h y métodos de uso de estas | |
BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
ECSP18039758A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
AR118602A1 (es) | Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih | |
ECSP18084491A (es) | Proteínas de unión triespecíficas y/o trivalentes | |
AR108210A1 (es) | Proteínas de unión triespecíficas y/o trivalentes | |
EA201892085A1 (ru) | Новые белки, полученные из альфа-1-микроглобулина, и их применение | |
EA201790790A1 (ru) | Антитела человека против vegfr-2/kdr | |
EA202191078A2 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv | |
UA114758U (xx) | Полімерна гелева композиція для відновлення пошкодженої шкіри | |
SG10201808583SA (en) | Hemostatic pharmaceutical composition | |
EA202090225A3 (ru) | Модифицированные менингококковые полипептиды fhbp |